![Claude Ramoni](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Claude Ramoni active positions
Companies | Position | Start | End |
---|---|---|---|
Aerium Therapeutics, Inc.
![]() Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | Director/Board Member | - | - |
Career history of Claude Ramoni
Statistics
International
United States | 2 |
Operational
Director/Board Member | 1 |
Sectoral
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Aerium Therapeutics, Inc.
![]() Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | Commercial Services |
- Stock Market
- Insiders
- Claude Ramoni
- Experience